CGS Speaks

Researchers are finding ways to address certain traumatic brain injuries that were once believed to be beyond recovery.

Mark Cuban's new approach to drug pricing offers hope for lower costs while highlighting the ongoing battle for fair and transparent medication pricing.

How an obscure drug became a household name, revolutionizing an industry in the process.

As an update to the recent FDA decision on MDMA-assisted therapy, new psychedelic treatments may require a different approach that reinforces ethical science.

The FDA will decide if the psychedelic drug MDMA will be the first newly approved treatment for PTSD in over two decades.

Longstanding gender inequalities have resulted in a lack of biomedical research focused on women’s health.

Animal models can help accelerate biomedical research.

Repeating past mistakes of the War on Drugs could limit neuroscience research on potential therapeutics, leaving patients without hope.

Harris Eyre, M.D., Ph.D. gave the keynote address at the Lab to Leaders event where he discussed his most recent findings on brain capital.

Advances in immunotherapy are increasing the quality of life and changing the prognoses for terminal cancer patients.